Onconetix, Inc. Proceeds from Notes Payable
Onconetix, Inc. (ONCO) reported Proceeds from Notes Payable of $247.20 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-08-13
- Onconetix, Inc. proceeds from notes payable for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Onconetix, Inc. proceeds from notes payable for the quarter ending 2026-03-31 was $247.20K, a 147.20% increase year-over-year.
- Onconetix, Inc. proceeds from notes payable for the quarter ending 2025-12-31 was $460.88K.
- Onconetix, Inc. proceeds from notes payable for the quarter ending 2025-09-30 was $400.00K, a 128.57% increase year-over-year.
- Onconetix, Inc. proceeds from notes payable for fiscal 2025 was $1.34M.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $247.20K 10-Q · filed 2026-08-13 | $708.07K derived: sum of 3 quarters · filed 2026-08-13 | $1.11M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $247.20K 10-Q · filed 2026-05-13 | $708.07K derived: sum of 2 quarters · filed 2026-05-13 | $1.11M derived: sum of 3 quarters · filed 2026-05-13 | $1.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $460.88K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $860.88K derived: sum of 2 quarters · filed 2026-03-13 | $1.24M derived: sum of 3 quarters · filed 2026-08-13 | $1.34M 10-K · filed 2026-03-13 |
| 2025-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $775.00K derived: sum of 2 quarters · filed 2026-08-13 | $875.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $375.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $475.00K 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-13 | |||
| 2024-09-30 | $175.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $175.00K derived: sum of 2 quarters · filed 2025-11-13 | $853.55K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $678.55K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $678.55K 10-Q · filed 2025-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |